Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Catatonia in Systemic Lupus Erythematosus.

NeuroSci·2025
Same author

When can calcium pyrophosphate deposition disease be considered a polymyalgia rheumatica mimicking disease?

Reumatologia·2025
Same author

Are There Definite Disease Subsets in Polymyalgia Rheumatica? Suggestions from a Narrative Review.

Healthcare (Basel, Switzerland)·2025
Same author

Polymyalgia Rheumatica (PMR) and Polymyalgia Rheumatica-like (PMR-like) Manifestations in Cancer Patients Following Treatment with Nivolumab and Pembrolizumab: Methodological Blurred Points Identified Through a Systematic Review of Published Case Reports.

Medical sciences (Basel, Switzerland)·2025
Same author

After what time interval are we justified to diagnose immune checkpoint inhibitor-mediated polymyalgia rheumatica?

Reumatismo·2025
Same author

Infective agents and polymyalgia rheumatica: key discussion points emerging from a narrative review of published literature.

Reumatologia·2024
Same journal

Sarcoma in patients with systemic lupus erythematosus. A systematic review.

Reumatologia·2026
Same journal

Late-onset systemic sclerosis: current concepts, uncertainties, and future practice guidelines.

Reumatologia·2026
Same journal

Clinical and laboratory differences in characteristics of patients with early-onset and late-onset systemic lupus erythematosus: a single-center retrospective study.

Reumatologia·2026
Same journal

A multicentre study for clinical phenotype prediction in juvenile dermatomyositis: categorical principal component analysis-based hierarchical clustering.

Reumatologia·2026
Same journal

Effect of dry needling therapy on hip range of motion as a component of functional performance in patients with chronic low back pain: a randomized clinical trial.

Reumatologia·2026
Same journal

Facial asymmetry and mandibular hypomobility as early indicators of temporomandibular joint involvement in juvenile idiopathic arthritis.

Reumatologia·2026
See all related articles

Related Experiment Video

Updated: Jun 18, 2026

Anti-Nuclear Antibody Screening Using HEp-2 Cells
13:01

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Published on: June 23, 2014

Seronegative polymyalgia rheumatica: an update

Ciro Manzo1

  • 1Internal and Geriatric Medicine Department, Azienda Sanitaria Locale Napoli 3 sud, Sant'Agnello, Naples, Italy.

Reumatologia
|June 17, 2026
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Last Updated: Jun 18, 2026

Anti-Nuclear Antibody Screening Using HEp-2 Cells
13:01

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Published on: June 23, 2014